The new GATA antibody
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)
Products
| Product | Manufacturer | Clone | Amount | Status | Order no. | Info | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ZR382 | 1 ml | Concentrate | CE/IVD | Z2673RL | |||||||||||||||||||||
|
ZR382 | 0.5 ml | Concentrate | CE/IVD | Z2673RS | |||||||||||||||||||||
|
ZR382 | 0.1 ml | Concentrate | CE/IVD | Z2673RT | |||||||||||||||||||||
|
ZR382 | 7 ml | r-t-u | CE/IVD | Z2673RP |
Further topics
Breast Cancer Awareness Month
Breast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.
New NGS-Assay for HRD determination
The AmoyDx® HRD Complete Panel is an advanced development of the AmoyDx® HRD Focus Panel, which is already established in many laboratories for determining homologous recombination deficiency (HRD).
